The latest announcement is out from Inogen ((INGN)).
Inogen, Inc. announced that it has received FDA 510(k) clearance for its Simeox 200 device, designed to enhance airway clearance and improve bronchial drainage for patients with chronic respiratory diseases. The authorization allows Inogen to expand its market in the United States and requires the company to make a payment of $13 million as part of an earlier agreement. This development marks a step forward in Inogen’s efforts to introduce innovative respiratory solutions and could have a potential impact on its market positioning and stakeholder engagement.
More about Inogen
Inogen, Inc. is a global medical technology company that specializes in innovative respiratory products for home care settings. The company develops, manufactures and markets advanced respiratory therapy devices to support patients with chronic respiratory conditions, partnering with patients, prescribers and distributors to enhance affordability.
YTD price performance: 56.28%
Average trading volume: 184,498
Technical Sentiment Consensus Rating: Buy it
Current market leader: $204.4 million
For an in-depth assessment of INGN shares, go to TipRanks stock analysis page.
https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607
2024-12-31 13:58:00
